Safety of statins: An update

Therapeutic Advances in Drug Safety

Volumn 3, Issue 3, 2012, Pages 133-144

  hu, Miao ^a   Cheung, Bernard M y ^b   Tomlinson, Brian ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

cardiovascular disease; drug safety; myopathy; rhabdomyolysis; statins

Indexed keywords

ALANINE AMINOTRANSFERASE; AMIODARONE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CERIVASTATIN; CLARITHROMYCIN; CYCLOSPORIN; CYTOCHROME P450 3A4; DANAZOL; DIGOXIN; DIURETIC AGENT; ERYTHROMYCIN; FLUCONAZOLE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KETOCONAZOLE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PITAVASTATIN; PLACEBO; PRAVASTATIN; RIFAMPICIN; ROSUVASTATIN; ROXITHROMYCIN; SIMVASTATIN; SULFAPHENAZOLE; TELITHROMYCIN; UNINDEXED DRUG; WARFARIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAIN HEMORRHAGE; CREATINE KINASE BLOOD LEVEL; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME INHIBITION; FOLLOW UP; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HEREDITY; HUMAN; INCIDENCE; KIDNEY INJURY; LIVER FUNCTION TEST; META ANALYSIS (TOPIC); MONOTHERAPY; MORBIDITY; MULTIPLE ORGAN FAILURE; MUSCLE TOXICITY; MYALGIA; MYOPATHY; NONALCOHOLIC FATTY LIVER; PHARMACOGENETICS; PHARMACOKINETICS; PHYSICAL CHEMISTRY; PRESCRIPTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHABDOMYOLYSIS; RISK FACTOR; SIDE EFFECT; TOXICITY; TREATMENT DURATION; VITAMIN D DEFICIENCY;

EID: 84868667498     PISSN: 20420986     EISSN: 20420994     Source Type: Journal    
DOI: 10.1177/2042098612439884     Document Type: Review

References (96)

1. Abd T.T. Jacobson T.A. (2011) Statin-induced myopathy: a review and update. Expert Opin Drug Saf 10: 373–387.
2. Ahmed W. Khan N. Glueck C.J. Pandey S. Wang P. Goldenberg N. (2009) Low serum 25 (OH) vitamin D levels (<32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients. Transl Res 153: 11–16.
3. Alsheikh-Ali A.A. Karas R.H. (2007) Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system). Am J Cardiol 99: 379–381.
4. Amarenco P. Bogousslavsky J. Callahan A. 3rd Goldstein L.B. Hennerici M. Rudolph A.E. (2006) High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355: 549–559.
5. Amarenco P. Labreuche J. (2009) Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 8: 453–463.
6. Argo C.K. Loria P. Caldwell S.H. Lonardo A. (2008) Statins in liver disease: a molehill, an iceberg, or neither? Hepatology 48: 662–669.
7. Armitage J. (2007) The safety of statins in clinical practice. Lancet 370(9601): 1781–1790.
8. Armitage J. Bowman L. Wallendszus K. Bulbulia R. Rahimi K. Haynes R. (2010) Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet 376: 1658–1669.
9. Athyros V.G. Tziomalos K. Gossios T.D. Griva T. Anagnostis P. Kargiotis K. (2010a) Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 376: 1916–1922.
10. Athyros V.G. Tziomalos K. Karagiannis A. Mikhailidis D.P. (2010b) Atorvastatin: safety and tolerability. Expert Opin Drug Saf 9: 667–674.
11. Athyros V.G. Tziomalos K. Karagiannis A. Wierzbicki A.S. Mikhailidis D.P. (2010c) Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association? Curr Opin Cardiol 25: 406–410.
12. Backes J.M. Howard P.A. Ruisinger J.F. Moriarty P.M. (2009) Does simvastatin cause more myotoxicity compared with other statins? Ann Pharmacother 43: 2012–2020.
13. Baigent C. Blackwell L. Emberson J. Holland L.E. Reith C. Bhala N. (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376: 1670–1681.
14. Baigent C. Keech A. Kearney P.M. Blackwell L. Buck G. Pollicino C. (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366: 1267–1278.
15. Bays H. (2006) Statin safety: an overview and assessment of the data–2005. Am J Cardiol 97: 6C–26C.
16. Bellosta S. Paoletti R. Corsini A. (2004) Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 109(23 Suppl. 1): III50–III57.
17. Beltowski J. Wojcicka G. Jamroz-Wisniewska A. (2009) Adverse effects of statins–mechanisms and consequences. Curr Drug Saf 4: 209–228.
18. Bersano A. Ballabio E. Lanfranconi S. Mazzucco S. Candelise L. Monaco S. (2008) Statins and stroke. Curr Med Chem 15: 2380–2392.
19. Bhatia L. Byrne C.D. (2010) There is a slight increase in incident diabetes risk with the use of statins, but benefits likely outweigh any adverse effects in those with moderate-to-high cardiovascular risk. Evid Based Med 15: 84–85.
20. Bottorff M.B. (2006) Statin safety and drug interactions: clinical implications. Am J Cardiol 97: 27C–31C.
21. Brewer H.B. Jr (2003) Benefit–risk assessment of rosuvastatin 10 to 40 milligrams. Am J Cardiol 92: 23K–29K.
22. Brown W.V. (2008) Safety of statins. Curr Opin Lipidol 19: 558–562.
23. Bruckert E. Hayem G. Dejager S. Yau C. Begaud B. (2005) Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients–the PRIMO study. Cardiovasc Drugs Ther 19: 403–414.
24. Bunout D. Barrera G. Leiva L. Gattas V. de la Maza M.P. Avendano M. (2006) Effects of vitamin D supplementation and exercise training on physical performance in Chilean vitamin D deficient elderly subjects. Exp Gerontol 41: 746–752.
25. Chatzizisis Y.S. Koskinas K.C. Misirli G. Vaklavas C. Hatzitolios A. Giannoglou G.D. (2010) Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf 33: 171–187.
26. Collins R. Armitage J. Parish S. Sleight P. Peto R. (2004) Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 363: 757–767.
27. Corsini A. Ceska R. (2011) Drug–drug interactions with statins: will pitavastatin overcome the statins’ Achilles’ heel? Curr Med Res Opin 27: 1551–1562.
28. da Silva P.M. (2011) Are all statins the same? Focus on the efficacy and tolerability of pitavastatin. Am J Cardiovasc Drugs 11: 93–107.
29. Davidson M.H. (2002) Combination therapy for dyslipidemia: safety and regulatory considerations. Am J Cardiol 90: 50K–60K.
30. De Caterina R. Scarano M. Marfisi R. Lucisano G. Palma F. Tatasciore A. (2010) Cholesterol-lowering interventions and stroke: insights from a meta-analysis of randomized controlled trials. J Am Coll Cardiol 55: 198–211.
31. del Sol A.I. Nanayakkara P.W. (2008) Pravastatin: an evidence-based statin? Expert Opin Drug Metab Toxicol 4: 821–825.
32. Donnelly L.A. Doney A.S. Tavendale R. Lang C.C. Pearson E.R. Colhoun H.M. (2011) Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study. Clin Pharmacol Ther 89: 210–216.
33. Elliott W.J. Meyer P.M. (2007) Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369: 201–207.
34. Erkal M.Z. Wilde J. Bilgin Y. Akinci A. Demir E. Bodeker R.H. (2006) High prevalence of vitamin D deficiency, secondary hyperparathyroidism and generalized bone pain in Turkish immigrants in Germany: identification of risk factors. Osteoporos Int 17: 1133–1140.
35. Everett B.M. Glynn R.J. MacFadyen J.G. Ridker P.M. (2010) Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Circulation 121: 143–150.
36. FDA (2010) FDA Drug Safety Communication: Ongoing safety review of high-dose Zocor (simvastatin) and increased risk of muscle injury. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm204882htm#TableofSimvastatinDoseLimitations. (accessed 20 October 2011).
37. FDA (2011) FDA Drug Safety Communication: New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. http://www.fda.gov/Drugs/DrugSafety/ucm256581.htm (accessed 20 October 2011).
38. Fiegenbaum M. da Silveira F.R. Van der Sand C.R. Van der Sand L.C. Ferreira M.E. Pires R.C. (2005) The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin Pharmacol Ther 78: 551–558.
39. Frishman W.H. Horn J. (2008) Statin–drug interactions: not a class effect. Cardiol Rev 16: 205–212.
40. Fung E.C. Crook M.A. (2011) Statin myopathy: a lipid clinic experience on the tolerability of statin rechallenge. Cardiovasc Ther 1 April [Epub ahead of print].
41. Gillett R.C. Jr Norrell A. (2011) Considerations for safe use of statins: liver enzyme abnormalities and muscle toxicitiy. Am Fam Physician 83: 711–716.
42. Glueck C.J. Abuchaibe C. Wang P. (2011a) Symptomatic myositis-myalgia in hypercholesterolemic statin-treated patients with concurrent vitamin D deficiency leading to statin intolerance may reflect a reversible interaction between vitamin D deficiency and statins on skeletal muscle. Med Hypotheses 77: 658–661.
43. Glueck C.J. Budhani S.B. Masineni S.S. Abuchaibe C. Khan N. Wang P. (2011b) Vitamin D deficiency, myositis-myalgia, and reversible statin intolerance. Curr Med Res Opin 27: 1683–1690.
44. Goldstein L.B. Amarenco P. Szarek M. Callahan A. 3rd Hennerici M. Sillesen H. (2008) Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology 70: 2364–2370.
45. Hackam D.G. Austin P.C. Huang A. Juurlink D.N. Mamdani M.M. Paterson J.M. (2012) Statins and intracerebral hemorrhage: a retrospective cohort study. Arch Neurol 69: 39–45.
46. Hackam D.G. Woodward M. Newby L.K. Bhatt D.L. Shao M. Smith E.E. (2011) Statins and intracerebral hemorrhage: collaborative systematic review and meta-analysis. Circulation 124: 2233–2242.
47. Holtzman C.W. Wiggins B.S. Spinler S.A. (2006) Role of P-glycoprotein in statin drug interactions. Pharmacotherapy 26: 1601–1607.
48. Hu M. Mak V.W.L. Chu T.T.Y. Waye M.M.Y. Tomlinson B. (2009) Pharmacogenetics of HMG-CoA reductase inhibitors: optimizing the prevention of coronary heart disease. Curr Pharmacogenom Person Med 7: 1–26.
49. Hu M. To K.K. Mak V.W. Tomlinson B. (2011) The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins. Expert Opin Drug Metab Toxicol 7: 49–62.
50. Ieiri I. Higuchi S. Sugiyama Y. (2009) Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin Drug Metab Toxicol 5: 703–729.
51. Jacobson T.A. (2009) Myopathy with statin-fibrate combination therapy: clinical considerations. Nat Rev Endocrinol 5: 507–518.
52. Josan K. Majumdar S.R. McAlister F.A. (2008) The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. CMAJ 178: 576–584.
53. Joy T.R. Hegele R.A. (2009) Narrative review: statin-related myopathy. Ann Intern Med 150: 858–868.
54. Kashani A. Phillips C.O. Foody J.M. Wang Y. Mangalmurti S. Ko D.T. (2006) Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 114: 2788–2797.
55. Kearney P.M. Blackwell L. Collins R. Keech A. Simes J. Peto R. (2008) Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371: 117–125.
56. LaRosa J.C. Grundy S.M. Waters D.D. Shear C. Barter P. Fruchart J.C. (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352: 1425–1435.
57. Law M. Rudnicka A.R. (2006) Statin safety: a systematic review. Am J Cardiol 97(8A): 52C–60C.
58. Law M.R. Wald N.J. Rudnicka A.R. (2003) Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 326: 1423.
59. Lee P. Greenfield J.R. Campbell L.V. (2009) Vitamin D insufficiency–a novel mechanism of statin-induced myalgia? Clin Endocrinol (Oxf) 71: 154–155.
60. Lewis J.H. Mortensen M.E. Zweig S. Fusco M.J. Medoff J.R. Belder R. (2007) Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 46: 1453–1463.
61. Link E. Parish S. Armitage J. Bowman L. Heath S. Matsuda F. (2008) SLCO1B1 variants and statin-induced myopathy–a genomewide study. N Engl J Med 359(8): 789–799.
62. Marcoff L. Thompson P.D. (2007) The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol 49: 2231–2237.
63. McKenney J.M. Davidson M.H. Jacobson T.A. Guyton J.R. (2006) Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 97: 89C–94C.
64. Musso G. Cassader M. Gambino R. (2011) Cholesterol-lowering therapy for the treatment of nonalcoholic fatty liver disease: an update. Curr Opin Lipidol 22: 489–496.
65. Neuvonen P.J. Niemi M. Backman J.T. (2006) Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 80: 565–581.
66. Newman C. Tsai J. Szarek M. Luo D. Gibson E. (2006) Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol 97: 61–67.
67. Niemi M. (2010) Transporter pharmacogenetics and statin toxicity. Clin Pharmacol Ther 87: 130–133.
68. Noda H. Iso H. Irie F. Sairenchi T. Ohtaka E. Doi M. (2009) Low-density lipoprotein cholesterol concentrations and death due to intraparenchymal hemorrhage: the Ibaraki Prefectural Health Study. Circulation 119: 2136–2145.
69. Oh J. Ban M.R. Miskie B.A. Pollex R.L. Hegele R.A. (2007) Genetic determinants of statin intolerance. Lipids Health Dis 6: 7.
70. Omar M.A. Wilson J.P. (2002) FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 36: 288–295.
71. Pasanen M.K. Neuvonen M. Neuvonen P.J. Niemi M. (2006) SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 16: 873–879.
72. Pasternak R.C. Smith S.C. Jr Bairey-Merz C.N. Grundy S.M. Cleeman J.I. Lenfant C. (2002) ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 40: 567–572.
73. Perez-Castrillon J.L. Vega G. Abad L. Sanz A. Chaves J. Hernandez G. (2007) Effects of atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Am J Cardiol 99: 903–905.
74. Peters B.J. Klungel O.H. Visseren F.L. de Boer A. Maitland-van der Zee A.H. (2009) Pharmacogenomic insights into treatment and management of statin-induced myopathy. Genome Med 1: 120.
75. Preiss D. Sattar N. (2011) Statins and the risk of new-onset diabetes: a review of recent evidence. Curr Opin Lipidol 22: 460–466.
76. Preiss D. Seshasai S.R. Welsh P. Murphy S.A. Ho J.E. Waters D.D. (2011) Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 305: 2556–2564.
77. Rejnmark L. Vestergaard P. Heickendorff L. Mosekilde L. (2010) Simvastatin does not affect vitamin d status, but low vitamin d levels are associated with dyslipidemia: results from a randomised, controlled trial. Int J Endocrinol 2010: 957174.
78. Ridker P.M. Danielson E. Fonseca F.A. Genest J. Gotto A.M. Jr Kastelein J.J. (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359: 2195–2207.
79. Rodriguez-Yanez M. Agulla J. Rodriguez-Gonzalez R. Sobrino T. Castillo J. (2008) Statins and stroke. Ther Adv Cardiovasc Dis 2: 157–166.
80. Romaine S.P. Bailey K.M. Hall A.S. Balmforth A.J. (2009) The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Pharmacogenomics J 10: 1–11.
81. Sampson U.K. Linton M.F. Fazio S. (2011) Are statins diabetogenic? Curr Opin Cardiol 26: 342–347.
82. Sattar N. Preiss D. Murray H.M. Welsh P. Buckley B.M. de Craen A.J. (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375: 735–742.
83. Shepherd J. Vidt D.G. Miller E. Harris S. Blasetto J. (2007) Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program. Cardiology 107: 433–443.
84. Tandra S. Vuppalanchi R. (2009) Use of statins in patients with liver disease. Curr Treat Options Cardiovasc Med 11: 272–278.
85. Thompson P.D. Clarkson P. Karas R.H. (2003) Statin-associated myopathy. JAMA 289: 1681–1690.
86. Thompson P.D. Clarkson P.M. Rosenson R.S. (2006) An assessment of statin safety by muscle experts. Am J Cardiol 97: 69C–76C.
87. Tirschwell D.L. Smith N.L. Heckbert S.R. Lemaitre R.N. Longstreth W.T. Jr Psaty B.M. (2004) Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups. Neurology 63: 1868–1875.
88. Toth P.P. Dayspring T.D. (2011) Drug safety evaluation of rosuvastatin. Expert Opin Drug Saf 10: 969–986.
89. Voora D. Shah S.H. Spasojevic I. Ali S. Reed C.R. Salisbury B.A. (2009) The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 54: 1609–1616.
90. Waters D.D. (2005) Safety of high-dose atorvastatin therapy. Am J Cardiol 96: 69F–75F.
91. Wilke R.A. Moore J.H. Burmester J.K. (2005) Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage. Pharmacogenet Genomics 15: 415–421.
92. Wolfe S.M. (2004) Dangers of rosuvastatin identified before and after FDA approval. Lancet 363: 2189–2190.
93. Yavuz B. Ertugrul D.T. Cil H. Ata N. Akin K.O. Yalcin A.A. (2009) Increased levels of 25 hydroxyvitamin D and 1,25-dihydroxyvitamin D after rosuvastatin treatment: a novel pleiotropic effect of statins? Cardiovasc Drugs Ther 23: 295–299.
94. Young J.M. Florkowski C.M. Molyneux S.L. McEwan R.G. Frampton C.M. George P.M. (2007) Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia. Am J Cardiol 100: 1400–1403.
95. Zamor P.J. Russo M.W. (2011) Liver function tests and statins. Curr Opin Cardiol 26: 338–341.
96. Zhao D. Liu J. Wang W. Zeng Z. Cheng J. Sun J. (2008) Epidemiological transition of stroke in China: twenty-one-year observational study from the Sino-MONICA-Beijing Project. Stroke 39: 1668–1674.